A New Era for Quantitative MRI Biomarkers of the Liver: A Challenge and Opportunity for the Radiology Community

HomeRadiologyVol. 313, No. 3 PreviousNext Reviews and CommentaryEditorialA New Era for Quantitative MRI Biomarkers of the Liver: A Challenge and Opportunity for the Radiology CommunityClaude B. Sirlin, Scott B. Reeder Claude B. Sirlin, Scott B. Reeder Author AffiliationsFrom the Department of Radiology, Liver Imaging Group, University of California San Diego, San Diego, Calif (C.B.S.); and Departments of Radiology, Medical Physics, Biomedical Engineering, Medicine, and Emergency Medicine, University of Wisconsin, 600 Highland Ave, E3/366, Madison, WI 53792 (S.B.R.).Address correspondence to S.B.R. (email: [email protected]).Claude B. SirlinScott B. Reeder Published Online:Dec 3 2024https://doi.org/10.1148/radiol.241876MoreSectionsFull textPDF ToolsAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookXLinked In References1. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. U.S. Food & Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Posted March 14, 2024. Accessed June 17, 2024. Google Scholar2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77(4):1335–1347. Medline Google Scholar3. van den Berg EH, Douwes RM, de Meijer VE, Schreuder TCMA, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis 2018;50(1):68–75. Medline Google Scholar4. Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 2022;34(7):969–977.e2. Medline Google Scholar5. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67(1):123–133. Medline Google Scholar6. Ma J, Hwang S-J, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol 2017;66(2):390–397. Medline Google Scholar7. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024;390(6):497–509. Medline Google Scholar8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. Medline Google Scholar9. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019;394(10213):2012–2024. Medline Google Scholar10. Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging 2012;36(5):1011–1014. Medline Google Scholar11. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging 2011;34(4):729–749. Medline Google Scholar12. Meisamy S, Hines CDG, Hamilton G, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011;258(3):767–775. Google Scholar13. Yokoo T, Shiehmorteza M, Hamilton G, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 2011;258(3):749–759. Google Scholar14. Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58(6):1930–1940. Medline Google Scholar15. Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology 2018;68(2):763–772. Medline Google Scholar16. Fowler KJ, Venkatesh SK, Obuchowski N, et al. Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium. Radiology 2023;309(1):e231092. Google Scholar17. Yokoo T, Serai SD, Pirasteh A, et al; RSNA-QIBA PDFF Biomarker Committee. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology 2018;286(2):486–498. Google Scholar18. Hernando D, Sharma SD, Aliyari Ghasabeh M, et al. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magn Reson Med 2017;77(4):1516–1524. Medline Google Scholar19. Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med 2008;60(5):1122–1134. Medline Google Scholar20. Yokoo T, Bydder M, Hamilton G, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009;251(1):67–76. Google Scholar21. Wang K, Cunha GM, Hasenstab K, et al. Deep Learning for Inference of Hepatic Proton Density Fat Fraction From T1-Weighted In-Phase and Opposed-Phase MRI: Retrospective Analysis of Population-Based Trial Data. AJR Am J Roentgenol 2023;221(5):620–631. Medline Google Scholar22. Selvaraj EA, Mózes FE, Jayaswal ANA, et al; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2021;75(4):770–785. Medline Google Scholar23. Pierce T, Ozturk A, Sherlock S, et al. Reproducibility and Repeatability of Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease: A Prospective Study. Radiology 2024;312(3):e233094. Google Scholar24. Duarte-Rojo A, Taouli B, Leung DH, et al. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024. 10.1097/HEP.0000000000000852. Published online March 15, 2024. Google Scholar25. Yin M, Ehman RLMR. MR Elastography: Practical Questions, From the AJR Special Series on Imaging of Fibrosis. AJR Am J Roentgenol 2024;222(1):e2329437. Medline Google Scholar26. Zhang YN, Fowler KJ, Boehringer AS, et al. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. Eur Radiol 2022;32(4):2457–2469. Medline Google Scholar27. Resmetirom Prior Authorization with Quantity Limit Program Summary. Blue Cross and Blue Shield of Minnesota. https://mn-policies.exploremyplan.com/portal/web/mn-policies/home/-/asset_publisher/gvKEs0SDu27L/content/ph-1215/78515. Published 2024. Accessed June 17, 2024. Google Scholar28. Rezdiffra (resmetirom). - Prior Authorization/Medical Necessity. UnitedHealthcare Commercial Plans. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Med-Nec-Rezdiffra.pdf. Published 2024. Accessed June 17, 2024. Google Scholar29. Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol 2022;76(4):781–787. Medline Google Scholar30. Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021;70(10):1946–1953. Medline Google Scholar31. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018;67(10):1477–1492. Medline Google Scholar32. Garrison LP Jr, Jiao B, Elsisi Z, et al. Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019. Value Health 2024;27(8):1021–1029. Medline Google Scholar33. Pooler BD, Hernando D, Reeder SB. Clinical Implementation of a Focused MRI Protocol for Hepatic Fat and Iron Quantification. AJR Am J Roentgenol 2019;213(1):90–95. Medline Google Scholar34. CMS.gov Physician Fee Schedule. Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/physician-fee-schedule/search. Accessed June 17, 2024. Google Scholar35. Hu HH, Yokoo T, Bashir MR, et al; RSNA Quantitative Imaging Biomarkers Alliance PDFF Biomarker Committee. Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom Study. Radiology 2021;298(3):640–651. Google Scholar36. Zhao R, Zhang Y, Wang X, et al. Motion-robust, high-SNR liver fat quantification using a 2D sequential acquisition with a variable flip angle approach. Magn Reson Med 2020;84(4):2004–2017. Medline Google Scholar37. Armstrong T, Zhong X, Shih S-F, et al. Free-breathing 3D stack-of-radial MRI quantification of liver fat and R2* in adults with fatty liver disease. Magn Reson Imaging 2022;85:141–152. Medline Google Scholar38. Colgan TJ, Zhao R, Roberts NT, Hernando D, Reeder SB. Limits of Fat Quantification in the Presence of Iron Overload. J Magn Reson Imaging 2021;54(4):1166–1174. [Published correction appears in J Magn Reson Imaging 2022;55(6):1910.] Medline Google Scholar39. Tamada D, van der Heijden RA, Weaver J, Hernando D, Reeder SB. Confidence maps for reliable estimation of proton density fat fraction and R2* in the liver. Magn Reson Med 2024;91(5):2172–2187. Medline Google Scholar40. Campo CA, Hernando D, Schubert T, Bookwalter CA, Pay AJV, Reeder SB. Standardized Approach for ROI-Based Measurements of Proton Density Fat Fraction and R2* in the Liver. AJR Am J Roentgenol 2017;209(3):592–603. Medline Google Scholar41. Zhong X, Nickel MD, Kannengiesser SAR, Dale BM, Kiefer B, Bashir MR. Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. Magn Reson Med 2014;72(5):1353–1365. Medline Google Scholar42. Wang K, Mamidipalli A, Retson T, et al; members of the NASH Clinical Research Network. Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network. Radiol Artif Intell 2019;1(2):180022. Google Scholar43. Dzyubak B, Li J, Chen J, et al. Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021;54(1):122–131. Medline Google Scholar44. Cunha GM, Delgado TI, Middleton MS, et al. Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance. AJR Am J Roentgenol 2022;219(2):224–232. Medline Google Scholar45. MRI-Based Proton Density Fat Fraction (PDFF) of the Liver. Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. Maintenance version. QIBA Proton Density Fat Fraction Biomarker Committee. https://qibawiki.rsna.org/images/6/63/MRI-Based_PDFF_of_the_Liver_QIBA_Profile_2024_06-19_CONSENSUS-maintenance.pdf. Posted June 19, 2024. Accessed October 1, 2024. Google Scholar46. MR Elastography of the Liver. Quantitative Imaging Biomarkers Alliance. Profile Stage: Clinically Feasible. Maintenance version. QIBA MR Biomarker Committee. https://qibawiki.rsna.org/index.php/MR_Elastography_of_the_Liver,_Clinically_Feasible_Profile. Posted November 7, 2023. Accessed October 1, 2024. Google Scholar47. Guglielmo FF, Barr RG, Yokoo T, et al. Liver Fibrosis, Fat, and Iron Evaluation with MRI and Fibrosis and Fat Evaluation with US: A Practical Guide for Radiologists. RadioGraphics 2023;43(6):e220181. Google Scholar48. Starekova J, Zhao R, Colgan TJ, et al. Improved free-breathing liver fat and iron quantification using a 2D chemical shift-encoded MRI with flip angle modulation and motion-corrected averaging. Eur Radiol 2022;32(8):5458–5467. Medline Google ScholarArticle HistoryReceived: June 26 2024Revision requested: July 15 2024Revision received: Oct 1 2024Accepted: Oct 7 2024Published online: Dec 03 2024 FiguresReferencesRelatedDetails Vol. 313, No. 3 Metrics Altmetric Score PDF download